PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of project...
Screening and exit interviews are particularly beneficial to inform the development of drugs for rare diseases. Interviewing patients can be helpful t...
Patient-focused insights - delivered directly to your inbox
Highlights on EMA’s focus to advance patient-centred access to medicines in partnership with healthcare systems. In EMA’s Regulatory Science Strategy...
As part of the EMA’s Regulatory Science Strategy to 2025, EMA proposes five strategic goals for human medicines regulation. Especially one of these fi...
The FDA and the EMA are strengthening Patient-Focused Drug Development. The US Food and Drug Administration (FDA) and the European Medicines Agency (E...
Traditional PROMs (consisting of closed-end questions) have for many years been applied to reveal the patients’ experiences of effects that you expect...
To ensure that you get a clearer picture of a new drug, we recommend interviewing users exposed to a drug candidate as early as possible in the trial...
